China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s ...

Illumina's leading sequencing technology, as well as its menu of DRAGEN-powered multiomics offerings, genomics AI tools and Illumina Connected Analytics platform, has streamlined genomic data ...

Illumina's (ILMN) stock slid 5% post-market after it released its Q4 earnings report and reiterated its 2025 guidance, ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and ...

Meanwhile, it doesn't seem coincidental that Illumina, which is the most significant genetic sequencing business in the world, has a large Chinese rival in biotech BGI Genomics. Ever feel like you ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

Illumina (ILMN-1.73%) is the industry leader in using short-read sequencing technology, which breaks DNA into short segments to aid in analysis for genetic research, testing, and medical treatment.